Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 14/20 | 0.50 |
| ▸ | CYBB | P04839 | 5/20 | 0.49 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242312 | 0.83 | NCF1 (0.56) | NCF1CYBBNOX5 | |
| SCHEMBL2242668 | 0.81 | GRM5 (0.54) | NCF1CYBBNOX5ALDH1A1 | |
| SCHEMBL2905129 | 0.81 | DCPS (0.50) | NCF1CYBBNOX5L3MBTL1 | |
| SCHEMBL28628561 | 0.80 | NCF1 (0.47) | NCF1CYBBNOX5ALDH1A1CYP2A6 | |
| SCHEMBL7810731 | 0.80 | NCF1 (0.51) | NCF1ALDH1A1GUSBL3MBTL1 | |
| SCHEMBL19690948 | 0.80 | SETDB1 (0.60) | NCF1CYBBNOX5CYP2A6 | |
| SCHEMBL19690971 | 0.80 | CYP3A4 (0.47) | NCF1CYBBNOX5CYP2A6 | |
| SCHEMBL12353493 | 0.77 | NCF1 (0.42) | NCF1CYBBNOX5ALDH1A1 | |
| SCHEMBL9190502 | 0.77 | NCF1 (0.62) | NCF1CYBBNOX5 | |
| SCHEMBL9189479 | 0.77 | NCF1 (0.62) | NCF1CYBBNOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946431-B2 | 2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-02-03 | — | — | US | disclosed |
| US-20140206876-A1 | 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-24 | — | — | US | disclosed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206876-A1 | 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists | GRM5, GRIK5, GRIA4 | NCF1 4211/4885CYBB 4535/4885NOX5 1728/4885 |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | NCF1 2172/4885CYBB 2363/4885NOX5 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.